205 related articles for article (PubMed ID: 22401771)
1. CD70 expression patterns in renal cell carcinoma.
Jilaveanu LB; Sznol J; Aziz SA; Duchen D; Kluger HM; Camp RL
Hum Pathol; 2012 Sep; 43(9):1394-9. PubMed ID: 22401771
[TBL] [Abstract][Full Text] [Related]
2. CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma.
Huang RR; Chen Z; Kroeger N; Pantuck A; Said J; Kluger HM; Shuch B; Ye H
Clin Genitourin Cancer; 2024 Apr; 22(2):347-353. PubMed ID: 38195301
[TBL] [Abstract][Full Text] [Related]
3. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.
Ruf M; Mittmann C; Nowicka AM; Hartmann A; Hermanns T; Poyet C; van den Broek M; Sulser T; Moch H; Schraml P
Clin Cancer Res; 2015 Feb; 21(4):889-98. PubMed ID: 25691774
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.
Pal SK; Forero-Torres A; Thompson JA; Morris JC; Chhabra S; Hoimes CJ; Vogelzang NJ; Boyd T; Bergerot PG; Adashek JJ; Li H; Yu X; Gartner EM; Carret AS; Smith DC
Cancer; 2019 Apr; 125(7):1124-1132. PubMed ID: 30624766
[TBL] [Abstract][Full Text] [Related]
5. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.
Gibney GT; Aziz SA; Camp RL; Conrad P; Schwartz BE; Chen CR; Kelly WK; Kluger HM
Ann Oncol; 2013 Feb; 24(2):343-349. PubMed ID: 23022995
[TBL] [Abstract][Full Text] [Related]
6. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.
Adam PJ; Terrett JA; Steers G; Stockwin L; Loader JA; Fletcher GC; Lu LS; Leach BI; Mason S; Stamps AC; Boyd RS; Pezzella F; Gatter KC; Harris AL
Br J Cancer; 2006 Aug; 95(3):298-306. PubMed ID: 16892042
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma.
Panowski SH; Srinivasan S; Tan N; Tacheva-Grigorova SK; Smith B; Mak YSL; Ning H; Villanueva J; Wijewarnasuriya D; Lang S; Melton Z; Ghosh A; Dusseaux M; Galetto R; Heyen JR; Sai T; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Cancer Res; 2022 Jul; 82(14):2610-2624. PubMed ID: 35294525
[TBL] [Abstract][Full Text] [Related]
8. CD70: a new tumor specific biomarker for renal cell carcinoma.
Junker K; Hindermann W; von Eggeling F; Diegmann J; Haessler K; Schubert J
J Urol; 2005 Jun; 173(6):2150-3. PubMed ID: 15879877
[TBL] [Abstract][Full Text] [Related]
9. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role.
Spatz S; Tolkach Y; Jung K; Stephan C; Busch J; Ralla B; Rabien A; Feldmann G; Brossart P; Bundschuh RA; Ahmadzadehfar H; Essler M; Toma M; Müller SC; Ellinger J; Hauser S; Kristiansen G
J Urol; 2018 Feb; 199(2):370-377. PubMed ID: 28827104
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
12. Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas.
Chaux A; Schultz L; Albadine R; Hicks J; Kim JJ; Allaf ME; Carducci MA; Rodriguez R; Hammers HJ; Argani P; Reuter VE; Netto GJ
Hum Pathol; 2012 Dec; 43(12):2129-37. PubMed ID: 22542128
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.
Pratt D; Pittaluga S; Palisoc M; Fetsch P; Xi L; Raffeld M; Gilbert MR; Quezado M
J Neuropathol Exp Neurol; 2017 Aug; 76(8):697-708. PubMed ID: 28789475
[TBL] [Abstract][Full Text] [Related]
14. CD70 Expression and Its Correlation with Clinicopathological Variables in Squamous Cell Carcinoma of the Head and Neck.
De Meulenaere A; Vermassen T; Aspeslagh S; Zwaenepoel K; Deron P; Duprez F; Ferdinande L; Rottey S
Pathobiology; 2016; 83(6):327-33. PubMed ID: 27389010
[TBL] [Abstract][Full Text] [Related]
15. Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications.
Kuehn A; Paner GP; Skinnider BF; Cohen C; Datta MW; Young AN; Srigley JR; Amin MB
Am J Surg Pathol; 2007 Oct; 31(10):1528-33. PubMed ID: 17895753
[TBL] [Abstract][Full Text] [Related]
16. Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma.
Benhamouda N; Sam I; Epaillard N; Gey A; Phan L; Pham HP; Gruel N; Saldmann A; Pineau J; Hasan M; Quiniou V; Nevoret C; Verkarre V; Libri V; Mella S; Granier C; Broudin C; Ravel P; De Guillebon E; Mauge L; Helley D; Jabla B; Chaput N; Albiges L; Katsahian S; Adam J; Mejean A; Adotevi O; Vano YA; Oudard S; Tartour E
Clin Cancer Res; 2022 Nov; 28(22):4983-4994. PubMed ID: 36067339
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays.
Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A
BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of CD24 in Clear Cell Renal Cell Carcinoma.
Arik D; Can C; Dündar E; Kabukçuoğlu S; Paşaoğlu Ö
Pathol Oncol Res; 2017 Apr; 23(2):409-416. PubMed ID: 27738793
[TBL] [Abstract][Full Text] [Related]
19. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic expression of Twist1, an EMT-related transcription factor, is associated with higher grades renal cell carcinomas and worse progression-free survival in clear cell renal cell carcinoma.
Rasti A; Madjd Z; Abolhasani M; Mehrazma M; Janani L; Saeednejad Zanjani L; Asgari M
Clin Exp Med; 2018 May; 18(2):177-190. PubMed ID: 29204790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]